Biochemical markers of hypertension, prehypertension

Turgunova, L.; Койчубеков, Б. К.; Turmuhambetova, Anar; Sorokina, Marina; Laryushina, Yelena; Korshukov, Ilya; Shalygina, Anna Andreevna; Baidildina, B.

doi:10.1016/j.ancard.2018.04.023

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant, negative correlation between endocan and BMI and leukocyte count was also shown [18]. Similar results were demonstrated by an even larger cross-sectional analysis of 938 normotensive, pre-hypertensive, and hypertensive subjects, showing significantly increased levels of circulating endocan concentration among patients with established HTN, indicative of endothelial dysfunction and target-organ damage [58]. In a previous cross-sectional study enrolling 90 patients with HTN and 44 normotensive subjects, it was shown that circulating endocan levels were significantly higher among hypertensive subjects, compared to normotensive controls, while an increase in endocan levels by 1 pg/mL was associated with an increase in the odds of the presence of HTN by 32.2% [11].…”

Section: Circulating Endocan Levels In Arterial Hypertensionsupporting

confidence: 75%

The Role of Endocan in Cardiometabolic Disorders

Klisić

Patoulias

2023

Metabolites

View full text Add to dashboard Cite

Discovered two decades ago, endocan still represents an intriguing biomarker related to inflammation. Endocan is a soluble dermatan sulphate proteoglycan secreted by endothelial cells. Its expression is observed in tissues related to the enhanced proliferation, especially hepatocytes, lungs, kidneys, etc. Endocan has been investigated in many cardiometabolic disorders that are tightly connected with inflammation, such as type 2 diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, kidney disease, obesity, polycystic ovary syndrome, metabolic syndrome, non-alcoholic fatty liver disease, etc. In this narrative, comprehensive review of the currently available literature, special attention will be paid to the role of endocan in the broad spectrum of cardiometabolic disorders. Since endocan has emerged as a novel endothelial dysfunction marker, the discovery of potential therapeutic strategies for patients with certain cardiometabolic risk factors would be of great importance to delay or even prevent the onset and progression of related complications, mainly cardiovascular.

show abstract

Section: Circulating Endocan Levels In Arterial Hypertensionsupporting

confidence: 75%

The Role of Endocan in Cardiometabolic Disorders

Klisić

Patoulias

2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…Finally, 15 articles involving a total of 3097 subjects met the inclusion criteria for our meta-analysis. [9–23] Of these, there were 8 papers about coronary artery disease (CAD), [10,12–18] 6 about hypertension, [9,11,15,16,22,23] and 3 about coronary flow slow [19–21] (Table 1). A flowchart of the study selection progress with specific reasons for exclusion is displayed in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease

Zhao¹,

Yao²,

Zhao

et al. 2018

Medicine

View full text Add to dashboard Cite

Objective:Endothelial dysfunction was widely regarded as the initial lesion in the multifactorial pathogenesis of cardiovascular disease (CVD). Serum endocan, a novel endothelial dysfunction biochemical marker, is involved in the development of CVD. Here, we fulfilled a meta-analysis to evaluate the association between CVD and serum endocan levels.Method:The relevant published literature was searched through large literature databases, including PubMed, Embase, Cochrane Library, SinoMed, and Web of Science, up to June 1, 2018. The data were extracted from the studies. Stata software was used to perform a meta-analysis.Result:Fifteen original studies with a total of 1839 patients and 1258 controls fulfilled the inclusion criteria and were included in the study dataset. Meta-analysis showed that the levels of serum endocan in patients with hypertension, coronary artery disease, and coronary slow flow were higher than those in the control group. The pooled standardized mean differences and 95% confidence intervals of endocan concentrations in those 3 groups were 0.53 [0.19–0.86], P < .01; 0.99 [0.51–1.39], P < .01; and 0.62 [0.45–0.78], P < .01, respectively. Further analysis showed that the level of serum endocan in hypertension patients with coronary artery disease was higher than that in patients with hypertension (0.61 [0.30–0.92], P < .01). Sensitivity analysis and subgroup analysis were use to confirm the above results.Conclusions:In this meta-analysis, we further confirmed that serum endocan level was significantly increased in the CVD population. The high serum endocan level may be one of the risk factors for CVD.

show abstract

“…In addition to its bene cial effect on high-density lipoprotein, niacin can also dilate peripheral blood vessels [47] [48]. In the pathogenesis of hypertension, endothelial dysfunction and immune system activation accompany the development of systemic in ammation and the production of in ammatory cytokines, and CD3 + are upregulated [49]. N-acetylserine has been a potential biomarker for severe sarcopenia and has not been reported in biomarker studies for hypertension [50].…”

Section: Discussionmentioning

confidence: 99%

Divergent indicator changes in different exercise states in non-hypertensive individuals and patients with hypertension

Zhang¹,

Xu²,

Gao³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Hypertension is a kind of clinical syndrome, characterized by the increase of systemic arterial pressure. There is a lack of identifiable triggers and predictors of hypertensive disease in response to treatment at rest and during exercise. In this study, a mathematical model was used to screen and compare the indicators and related changes at rest and during exercise between normotensive and hypertensive individuals. Methods Blood pressure and ultrasound-related indicators, blood biochemical indicators and metabolic compounds were collected and logistic regression model and Principal component analysis (PCA) were used to explore the differences of indexes at rest and in different exercise states in healthy and hypertensive patients. An indicator change map for hypertension is established. Results The results reveal that hypertension is not only related to oxidative stress, inflammatory reaction and fatty acid oxidation, but also involves various amino acid metabolism. The defined mathematical models and indicators changes during exercise might be helpful for early screening of hypertension and future studies are needed to explore their value on prevention and control of hypertension. Conclusion The research shows that the main regulation indicators at different exercise states differ significantly in the normal group and the hypertensive group. The key indicators of the normal group are blood pressure and ultrasound related indicators, while those of the hypertensive group are metabolites related to lactic acid metabolism, glycolysis, aerobic oxidation and lipid metabolism.

show abstract

Biochemical markers of hypertension, prehypertension

Cited by 8 publications

References 20 publications

The Role of Endocan in Cardiometabolic Disorders

The Role of Endocan in Cardiometabolic Disorders

The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease

Divergent indicator changes in different exercise states in non-hypertensive individuals and patients with hypertension

Contact Info

Product

Resources

About